NCT00931385 - Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

April 30, 2010

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

BI 1744

BI1744 Respimat Med Dose Once Daily

DRUG

bi1744

1744 low dose

DRUG

Placebo

Placebo Respimat and Foradil Placebo

DRUG

Foradil

Foradil 12 mcg twice daily and Placebo Respimat

Trial Locations (11)

1222.24.24011 Boehringer Ingelheim Investigational Site, Tampa

1222.24.24009 Boehringer Ingelheim Investigational Site, Overland Park

1222.24.24007 Boehringer Ingelheim Investigational Site, Lafayette

1222.24.24002 Boehringer Ingelheim Investigational Site, Cincinnati

1222.24.24010 Boehringer Ingelheim Investigational Site, Oklahoma City

1222.24.24004 Boehringer Ingelheim Investigational Site, Easley

1222.24.24006 Boehringer Ingelheim Investigational Site, Gaffney

1222.24.24005 Boehringer Ingelheim Investigational Site, Greenville

1222.24.24008 Boehringer Ingelheim Investigational Site, Greenville

1222.24.24001 Boehringer Ingelheim Investigational Site, Spartanburg

1222.24.24003 Boehringer Ingelheim Investigational Site, Union